Stallergenes report growth in third quarter results

22 October 2013

French allergy specialists Stallergenes (Euronext Paris: GENP) has released its third quarter results showing revenue growth of 3.6%.

The company’s third quarter sales were 45.9 million euros ($62.7 million), up 3.6% compared to the same period in 2012. France continued its growth, offsetting the impact of the negative performance of Italy and Spain due to the unfavorable overall economic climate, the company said. Other European countries achieved a 15.4% revenue increase, thanks to the 61% growth of Oralair, its grass pollen sublingual immunotherapy tablet, in Germany and including a prior period adjustment related to the rebate in Germany (1.1 million euros).

Sales of Oralair boost growth

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK